DK52189D0 - Farmaceutisk praeparat indeholdende igf i samt fremgangsmaade til fremstilling deraf - Google Patents

Farmaceutisk praeparat indeholdende igf i samt fremgangsmaade til fremstilling deraf

Info

Publication number
DK52189D0
DK52189D0 DK052189A DK52189A DK52189D0 DK 52189 D0 DK52189 D0 DK 52189D0 DK 052189 A DK052189 A DK 052189A DK 52189 A DK52189 A DK 52189A DK 52189 D0 DK52189 D0 DK 52189D0
Authority
DK
Denmark
Prior art keywords
procedures
preparing
pharmaceutical preparation
preparation containing
containing igf
Prior art date
Application number
DK052189A
Other languages
English (en)
Other versions
DK169233B1 (da
DK52189A (da
Inventor
Ernst Rudolf Froesch
Hans-Peter Guler
Christoph Schmid
Juergen Zapf
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of DK52189D0 publication Critical patent/DK52189D0/da
Publication of DK52189A publication Critical patent/DK52189A/da
Application granted granted Critical
Publication of DK169233B1 publication Critical patent/DK169233B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK052189A 1988-02-05 1989-02-03 Anvendelse af IGF I til fremstilling af et farmaceutisk præparat til behandling og forebyggelse af sekundærvirkninger af hyperinsulinæmi hos diabetikere behandlet med insulin DK169233B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP88810072 1988-02-05
EP88810072 1988-02-05

Publications (3)

Publication Number Publication Date
DK52189D0 true DK52189D0 (da) 1989-02-03
DK52189A DK52189A (da) 1989-08-06
DK169233B1 DK169233B1 (da) 1994-09-19

Family

ID=8200571

Family Applications (1)

Application Number Title Priority Date Filing Date
DK052189A DK169233B1 (da) 1988-02-05 1989-02-03 Anvendelse af IGF I til fremstilling af et farmaceutisk præparat til behandling og forebyggelse af sekundærvirkninger af hyperinsulinæmi hos diabetikere behandlet med insulin

Country Status (13)

Country Link
US (1) US4988675A (da)
EP (1) EP0331630B1 (da)
JP (1) JP2831017B2 (da)
KR (1) KR0131087B1 (da)
AU (1) AU624595B2 (da)
CA (1) CA1336815C (da)
DE (1) DE68905205T2 (da)
DK (1) DK169233B1 (da)
IE (1) IE63163B1 (da)
IL (1) IL89166A0 (da)
NZ (1) NZ227857A (da)
PH (1) PH26085A (da)
ZA (1) ZA89855B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440928B1 (en) 1988-12-06 2002-08-27 Colorado State University Research Foundation Method for treating diabetic neuropathy with NGF
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5128320A (en) * 1990-01-18 1992-07-07 Genentech, Inc. Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
JPH06510065A (ja) * 1992-06-08 1994-11-10 カイロン　コーポレーション 成長因子ｉｇｆ−ｉおよび／またはｉｇｆ−ｉｉの用法
US20070078089A1 (en) * 1992-07-06 2007-04-05 Ishii Douglas N Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II
DE69305091T2 (de) * 1992-10-29 1997-03-13 Genentech Inc Methode zur behandlung oder verhütung von fettleibigkeit
AU683043B2 (en) * 1993-01-25 1997-10-30 Beth Israel Hospital Association, The Method for modifying, diagnosing, and screening for IGF-I sensitive cell barrier properties
US5446024A (en) * 1993-12-17 1995-08-29 Genentech, Inc. Purification of insulin-like growth factor
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US5916569A (en) * 1997-03-26 1999-06-29 E. Martin Spencer Human erectile dysfunction and methods of treatment
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU762351B2 (en) * 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
ATE251466T1 (de) * 1999-04-08 2003-10-15 Genentech Inc Zusammensetzung auf basis gegensätzlich geladener polypeptide
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
EP1196189A2 (en) * 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
DE60141759D1 (de) * 2000-08-29 2010-05-20 Aurogen Inc Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf
BR0207422A (pt) * 2001-02-09 2005-04-19 Genentech Inc Cristal formado por igf-1, composição, método de tratamento de mamìferos que sofrem de disfunção de um agonista, método de cristalização de igf-1, igf-1 cristalino, métodos de identificação de agonistas indiretos de igf-1, complexo co-cristalino, método de determinação de estrutura tridimensional de igf-1, meio de armazenagem de dados legìvel por máquina, cristal de igf-1, método de uso de estrutura tridimensional de igf-1, método de identificação de agonistas ou antagonistas de igf-1, método de projeto de composto, método de identificação de peptidomimético, método de determinação de pelo menos uma parte de estrutura tridimensional de um complexo molecular, método de avaliação da capacidade de uma entidade quìmica de associar-se com igf-1, entidade quìmica, derivado de átomo pesado, método de avaliação experimental ou computacional de uma entidade quìmica e uso de uma composição
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
WO2002072780A2 (en) * 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
WO2005020898A2 (en) * 2003-08-21 2005-03-10 Tercica, Inc. Methods of reducing visceral fat by increasing levels of insulin-like growth factor-i (igf-i)
CA2577017A1 (en) * 2004-08-30 2006-03-09 Tercica, Inc. Method and device for diagnosing and treating insulin-like growth factor deficiency disorders
KR102288366B1 (ko) * 2018-03-09 2021-08-10 경북대학교 산학협력단 한속단 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE95236T1 (de) * 1983-04-25 1993-10-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren.

Also Published As

Publication number Publication date
JPH01233227A (ja) 1989-09-19
AU624595B2 (en) 1992-06-18
DK169233B1 (da) 1994-09-19
ZA89855B (en) 1989-10-25
EP0331630B1 (en) 1993-03-10
EP0331630A1 (en) 1989-09-06
PH26085A (en) 1992-02-06
IL89166A0 (en) 1989-09-10
IE63163B1 (en) 1995-03-22
DK52189A (da) 1989-08-06
DE68905205D1 (de) 1993-04-15
DE68905205T2 (de) 1993-07-22
IE890357L (en) 1989-08-05
KR0131087B1 (ko) 1998-04-17
KR890012667A (ko) 1989-09-18
CA1336815C (en) 1995-08-29
US4988675A (en) 1991-01-29
JP2831017B2 (ja) 1998-12-02
NZ227857A (en) 1992-04-28
AU2899989A (en) 1989-08-10

Similar Documents

Publication Publication Date Title
DK52189D0 (da) Farmaceutisk praeparat indeholdende igf i samt fremgangsmaade til fremstilling deraf
DK510384D0 (da) Laegemiddeltilberedning til intravenoes injektion samt fremgangsmaadetil fremstilling heraf
DK147488A (da) Benzoxazolderivat samt fremgangsmaade til fremstilling deraf
DK164868C (da) Imidazooe4,5-baaquinolin-2-on-derivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse
DK128688A (da) Thiazolderivater og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende derivaterne
DK328586D0 (da) Phenylethanolaminotetraliner og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende dem
DK454188D0 (da) 2-oxo-1-sulfonylaminocarbonyl-azetidiner samt fremgangsmaade til deres fremstilling
DK64183D0 (da) Farmaceutisk praeparat samt fremgangsmade til fremstilling deraf
DK166355C (da) Adenosin-derivater samt farmaceutiske praeparater indeholdende saadanne derivater
DK642588A (da) Indanderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende samme
DK592189A (da) Nitroimidazoler, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende samme
DK114584D0 (da) Fast farmaceutisk praeparat samt fremgangsmaade til fremstilling deraf
DK143188D0 (da) Farmaceutiske praeparater indeholdende pyranoquinolinforbindelser samt deres anvendelse
DK469189A (da) Substituerede thienopyraner, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende samme
DK160283C (da) Farmaceutisk iodoforpraeparat samt fremgangsmaade til fremstilling deraf
DK191086D0 (da) Benzisoselenazolonylderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse
DK614589D0 (da) Imidazolholdige peptider samt fremgangsmaade til fremstilling deraf
DK645988D0 (da) Biphenylderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeprater indeholdende samme
DK404587D0 (da) 5-deoxy-5-flourkanamycin b-derivater samt fremgangsmaader til fremstilling deraf
DK39388D0 (da) Isoxazol-derivater, fremgangsmaade til fremstilling heraf samt farmaceutiske praeparater indeholdende saadanne derivater
DK304789D0 (da) Saccharid og fremgangsmaade til fremstilling deraf samt farmaceutisk middel indeholdende saccharidet
DK354789D0 (da) Alkenyltetrazolderivater samt fremgangsmaade til fremstilling deraf
DK160827C (da) Pteridinderivater, fremgangsmaade til fremstilling heraf samt farmaceutisk praeparat
DK165293C (da) Quinoxalinforbindelser, fremgangsmaade til fremstilling deraf, samt farmaceutiske praeparater indeholdende forbindelserne
DK165294C (da) Quinoxalinforbindelser, fremgangsmaade til fremstilling deraf, samt farmaceutiske praeparater indeholdende forbindelserne

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired